

# AREXVY Billing and Coding: Quick Reference Guide

## Purpose

This guide is intended to provide billing and coding information that may be useful for reimbursement of AREXVY. This guide is not intended to serve as a comprehensive training for medical billing and coding, nor is it intended to direct the use of AREXVY for individual patients. Only a trained medical professional using professional judgement and clinical skills can make the informed decision about when to administer AREXVY to a particular patient, and coding will depend on such use.

## ICD-10-CM diagnosis code<sup>1\*</sup>

The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) is a system used to classify and code all diagnoses, identifying why a patient needs treatment by documenting the medical necessity.

ICD-10-CM code	Description
Z23	Encounter for immunization

\*ICD-10-CM code Z23, Encounter for Immunization, is reported for all vaccines given within an encounter; additional ICD-10-CM coding may be needed.<sup>1</sup>

## NDC<sup>2</sup>

The National Drug Code (NDC) is a three-segment, 10- or 11-digit number that serves as the FDA's identifier of drugs.

- Note that some payers require an 11-digit NDC, which involves adding a "0" immediately after the first hyphen in each GSK NDC. For example, when reporting NDC 58160-848-11 to a payer requiring an 11-digit NDC, it becomes NDC 58160-0848-11. Please check with your payer to understand which format is required.
- Some payers require an NDC in addition to the CPT code for the product. In such cases, it is important to format the NDC correctly or the claim will be denied, and you will need to resubmit a corrected claim in order to be reconsidered for payment.
- NDCs for AREXVY correlate to the outer carton. Most payers recognize the outer carton for billing purposes. Note: when completing CMS-1500 Claim Form, the qualified "N4" should be used immediately before the NDC.

Product	10-digit NDC	11-digit NDC
Outer Carton (supplied as package of 10 doses)	58160-848-11	58160-0848-11

## Indication

AREXVY is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older.

## Important Safety Information

- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY
- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of AREXVY

Please see additional Important Safety Information throughout and full [Prescribing Information](#) for AREXVY.

**AREXVY**  
(RESPIRATORY SYNCYTIAL VIRUS  
VACCINE, ADJUVANTED)

### CPT Code<sup>3</sup>

Current Procedural Terminology (CPT) codes are part of a coding system published and maintained by the American Medical Association, and they generally consist of 5-digit numeric codes that identify services and procedures.

CPT Code <sup>4</sup>	Description
90679	Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), one vaccine (single or combination vaccine/toxoid)
90472	Each additional vaccine administered during same encounter

### CVX and MVX Codes

CVX codes are used to identify the type of product used in an immunization. MVX codes are used to identify the manufacturer of a vaccine.

Code	Description
CVX <sup>5</sup>	303
MVX <sup>6</sup>	SKB

### Modifiers

Depending upon Payer requirement and level of visit, a modifier may be necessary. Please visit <https://gskpro.com/en-us/therapy-areas/vaccines/coding/vaccine-services/> for additional information.

### Medicare Billing

For Medicare Part D patients (pharmacy benefit), AREXVY may be administered at an in- or out-of-network retail pharmacy. Prescribers enrolled in a web-assisted portal for Medicare Part D vaccines administered in-office may electronically submit out-of-network claims to Medicare Part D plans for AREXVY.<sup>7</sup>

### Important Safety Information (cont'd)

- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY

Please see additional Important Safety Information throughout and full [Prescribing Information for AREXVY](#).

## Completing the CMS-1500 Claim Form<sup>2</sup>

The CMS-1500 form is a paper version health insurance claim form for non-institutional providers. The electronic version is called an 837 file. It is used to report and bill medical claims prepared and submitted by most physicians and suppliers for a physician's professional services.

A. _____		B. _____		C. _____		D. _____		23. PRIOR AUTHORIZATION NUMBER			
E. _____		F. _____		G. _____		H. _____					
I. _____		J. _____		K. _____		L. _____					
24. A. DATE(S) OF SERVICE				B. PLACE OF SERVICE	C. EMG	D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances)		E. DIAGNOSIS POINTER	F. \$ CHARGES	G. DAYS OR UNITS	H. EPSDT Family Plan
MM	DD	YY	MM	DD	YY		CPT/HCPCS	MODIFIER			
1	N458160084811 UN1										
2											

When submitting to payers who require NDC in addition to a CPT code, the NDC must be formatted correctly to avoid a claim denial.

- Enter the NDC in line 24A of the claim form:
  - Start with qualifier “N4” followed immediately (with no space) by the 11-digit NDC number with no hyphens
  - GSK vaccines typically have 10-digit NDCs, so a “0” must be added immediately after the first hyphen in each NDC
- Next, add 1 space after the NDC to record Unit of Measure & Quantity.
- Finally, add the Unit of Measure and Units Dispensed:
  - For reconstituted products, use Unit of Measure “UN” followed by the number of units administered (eg, UN1)

### Commercial and Medicare Plan Coverage

AREXVY is expected to be covered for most patients aged 60 years and older<sup>8,9</sup>

#### For Commercial Plans per the Affordable Care Act\*:

Most patients will pay **\$0** for AREXVY when administered in network.<sup>8</sup>

#### For Medicare Part D per the Inflation Reduction Act†:

Patients will pay **\$0** out of pocket for AREXVY<sup>9</sup>

For additional questions, please visit [gskpro.com/en-us/therapy-areas/vaccines/coding/vaccine-services/](https://gskpro.com/en-us/therapy-areas/vaccines/coding/vaccine-services/) or contact the GSK Vaccines Reimbursement Support Center at 855-636-8291.

\*Coverage, coding, cost to patient, reimbursement amount for product, and administration fee will vary by payer, plan, patient, professional setting, or services rendered, and are subject to change without notice. Cost to patients may vary. Coverage and reimbursement decisions are made by individuals following receipt of claims from providers. Providers must follow documentation and billing requirements of payer.

†For Medicare Part D patients (pharmacy benefit), AREXVY may be administered at an in- or out-of-network retail pharmacy. Prescribers enrolled in a web-assisted portal for Medicare Part D vaccines administered in-office may electronically submit out-of-network claims to Medicare Part D plans for AREXVY.<sup>7</sup>

### Important Safety Information (cont'd)

- The most commonly reported adverse reactions ( $\geq 10\%$ ) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
- Vaccination with AREXVY may not result in protection of all vaccine recipients

Please see additional Important Safety Information throughout and full [Prescribing Information for AREXVY](#).



## References:

1. Centers for Medicare & Medicaid Services. 2023 ICD-10-CM official guidelines for coding and reporting. Accessed June 24, 2023. <https://www.cms.gov/files/document/fy-2023-icd-10-cm-coding-guidelines-updated-01/11/2023.pdf>
2. Centers for Medicare & Medicaid Services. Medicare claims processing manual chapter 26: completing and processing form CMS-1500 data set. Rev. 11037, May 2022. Accessed June 24, 2023. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c26pdf.pdf>
3. American Medical Association. CPT® overview and code approval. Accessed June 24, 2023. <https://www.ama-assn.org/practice-management/cpt/cpt-overview-and-code-approval>
4. American Medical Association. CPT category I new vaccine codes (including incorporation of ACIP abbreviations listings) long descriptors. Accessed June 23, 2023. <http://www.ama-assn.org/system/files/vaccine-long-descriptors.pdf>
5. Centers for Disease Control and Prevention. Immunization information systems (IIS): Current HL7 standard code set, CVX – vaccines administered. Accessed June 24, 2023. <https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx>
6. Centers for Disease Control and Prevention. Immunization information systems (IIS): HL7 standard code set, MVX – manufacturers of vaccines. Accessed June 24, 2023. <https://www.2a.cdc.gov/vaccines/IIS/IISStandards/vaccines.asp?rpt=mvx>
7. Centers for Medicare & Medicaid Services. MLN fact sheet: Medicare Part D vaccines. Accessed July 24, 2023. <https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/downloads/vaccines-part-d-factsheet-icn908764.pdf>
8. Centers for Medicare & Medicaid Services. Preventive care benefits for adults. Accessed June 24, 2023. <https://www.healthcare.gov/preventive-care-adults/>
9. Centers for Medicare & Medicaid Services. IRA insulin vaccines memo: contract year 2023 program guidance related to Inflation Reduction Act changes to Part D coverage of vaccines and insulin. Accessed June 24, 2023. <https://www.cms.gov/files/document/irainsulinvaccinesmemo09262022.pdf>

Please see Important Safety Information on pages 1-3 and full [Prescribing Information](#) for AREXVY.

Trademarks are property of their respective owners.



©2023 GSK or licensor.  
RSALBND230035 July 2023  
Produced in USA.